# Index

## A

Access to Medicines Regime (Regimen de Acceso de Excepción a Medicamentos) (RAEM) 65  
Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) 64  
Advancing Hope Act 12  
Agência Nacional de Vigilância Sanitária (ANVISA) 60, 66  
All Wales Medicines Strategy Group (AWMSG) 104  
Argentina  
  biologic and synthetic drug registration process 65  
  Ministry of Health (MoH) 64  
  rare diseases 65  
Armenia 155  
Article 7 Procedure 78  
Article 8 Procedure 78  
Article 30 Procedure 78  
attention-deficit/hyperactivity disorder software approval 50  
Australia  
  definitions and guidelines 120–127  
  ICH guidelines recognized 120  
  legal framework 119  
  market access for devices 123  
  medical device regulation 121  
  pediatric cluster call participation 121  
  pediatric exclusivity 120

## B

Best Pharmaceuticals for Children Act (BPCA) 7, 9  
BiliTouch, model Motif Phototherapy Blanket approval 50  
biocompatibility testing 49, 50  
biological products  
  clinical trials for 69  
  pediatric exclusivity 14  
Brazil  
  incentives for development 65  
  pediatric product development 65  
Brexit 97

## C

Canada  
  drug regulations 53  
  ICH guidelines adoption 53–57  
  initiatives and incentives 54  
  market access 55  
  Marketing Authorization application 55  
  regulatory agencies/authorities 56  
  reimbursement 56  
Canadian Agency for Drugs and Technologies in Health (CADTH) 55  
Center for Devices and Radiological Health (CDRH) 45, 46, 49, 51  
Center for Drug Evaluation ((CDE) China) 130  
Central Drugs Standard Control Organization (CDSCO) 143  
Centro para el Control Estatal de los Medicamentos, Equipos y Dispositivos Médicos (CECMED) 67
Index

Children’s Development Program 130
Chile
  clinical trials 68
  healthcare insurance system 68
  regulatory standards 68
China
  case studies 138–142
  CDE consultation meetings 137
  consultation meetings with CDE 138
  directives on pediatric medicines 129
  drug pricing 139–142
  drug reimbursement 140–142
  financial incentive for medicines 130
  laws, regulations and directives 131
  license renewal 138
  MAA procedures 132–142
  marketing authorization procedures 139
  pediatric-specific regulation formulation 129–142
  postapproval change management 138
  priority review and approval procedure 130
  regulatory requirements 129
  technical guidance documents 133
clinical trials
  Argentina 64
  biological products 69
  Brazil 66
  Canada 55
  Chile 68
  Columbia 66
  Japanese standards for 116
  Latin America and Caribbean region 62
  Mexico 69
  natural history study for external control 40
  procedures in China 137
  regulations in India 146, 149
  Rest of World summary 161
collaboration
  Enpr-EMA 3
  India 149
  memorandums of understanding (India) 148
  Pediatric Cluster Meetings 2
  PMDA and foreign agencies 114
  protocol assistance (EMA) 92
  collaborative agreements
    India 148
  Colombia
    production and distribution hub 66
  Colombian Federation of Rare Diseases (FECOER) 67
  Colombia
    regulatory standards in 66
  Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) 69
  Committee for Advanced Therapeutic Medicinal Products (CAT) 92
  Committee for Human Medicinal Products (CHMP)
    Scientific Advice Working Party 92
  Committee for Medicinal Products for Human Use (CHMP)
    PDCO appointments 76
  Committee for Orphan Medicinal Products (COMP) 92
compassionate use
  Brazil 66
  Chile 68
  Cuba 67
  Latin America and Caribbean region 62
  Mexico 69
compliance
  limitations of check for children 86
  Paediatric Investigation Plan 89, 101
  PDCO and NCAs in 76
  PIP requirements for 77
compliance check
  for Marketing Authorization 89
  for patent protection extension 87
  PDCO opinion and 87
  reward linked to 90
  UK Marketing Authorization application 101
Comprehensive Economic Partnership Agreements (CEPA) 151
Coordination Group for Mutual Recognition and Decentralized Procedures Human (CMDh) 98
Coronavirus Response and Relief Supplemental Consolidated Appropriations Act 12
Cuba 67
D

data extrapolation
ICH guidelines for 1, 91
in pediatric device development 48
in pediatric investigation plan 17, 81
in pediatric product development 23
modeling and simulation 28
pediatric modeling for 138
proposals for 86
under PREA 8
decentralised (national) marketing authorisations 76, 77, 87, 89

E

Egypt 155
End-of-Phase (EOP) 12
Ethics Program 7
European Commission (EC)
history of actions on pediatric medicinal products 73–96
pediatric medicinal product regulatory actions 73
European database 91
European Medicines Agency (EMA)
approval procedure 79
development tools from 91
collaboration with India 149
compliance check request 89
deferral or waiver for UK 97
interactions of 92
network for pediatric expertise 91
Pediatric Cluster meetings 2
regulation waivers from 73
scientific advice procedure 79
trial data submission 91
UK alignment with 97
European Network of Paediatric Research 91
European Network of Paediatric Research (Enpr-EMA) 3
European Union (EU)
EU-PIP vs UK-PIP 100
PUMA for 90
postauthorization requirements 90

F

FDA Reauthorization Act (FDARA) 12
Federación Chilena de Enfermedades Raras (FECHER) 68
Federación Colombiana de Enfermedades Raras (FECOER) 67
Federación Mexicana de Enfermedades Raras (FEMEXER) 69
510(k) Premarket Notification 50
Food and Drug Administration Amendments Act (FDAAA) 8
Food and Drug Administration Modernization Act (FDAMA) 7
Food and Drug Administration Safety and Innovation Act (FDASIA) 11
full switch. See Rx-to-OTC switch process
Fundación de Enfermedades Lisosomales Chile (FELCH) 68

G

Global Pediatric Clinical Trials Network 3
Global Pediatric Research Networks 3
Good Clinical Practice (GCP)
adherence in LAC region 60, 62
inspections in Japan 113
United States 27
Good Manufacturing Practice (GMP)
application in India 150
development 49
device use 47
inspections in Japan 113
guidance documents
China 133
clinical guidelines (TGA) 123
E11 adoption (Japan) 113
FDA guidance for pediatric devices 47
general use for devices 48–52
pediatric device use 47
pediatric investigation plan (UK) 99
research involving children (India) 148

H

Health Ministry’s Screening Committee (HMSC), 148
Health Technology Assessment (HTA) agencies
UK criteria for orphan products 104
highly specialized technologies (HST) 104
Human Medicines (Amendments) 97
Index

Human Medicines Regulations 2012  97
Human Medicines Regulations (HMRs)  97
submission of pediatric studies  104

I
incentives for development
  Canada  54
  India
  collaborative research with other countries  148
  disease regulations/initiatives timeline  145
  drug development  143
  drug development schedules  147
  history of development  143
  marketing applications in  151
  pediatric drug development status  143
Indian Council of Medical Research (ICMR)
  National Ethical Guidelines for Biomedical
  Research Involving Children  148
Indonesia  155
initial pediatric study plan (iPSP). See Pediatric
  Study Plan (PSP)
  exemptions for submission  15
  procedure for  15
  Switzerland  110
  template and contents for PSP  18
United States  5
Institute for Social Security and Services for
  State Workers (ISSSTE)  69
Institut national d'excellence en santé et en
  services sociaux (INESSS)  56
Instituto Nacional de Vigilancia de
  Medicamentos y Alimentos (INVIMA)
  66
International Council for Harmonisation
  of Technical Requirements for
  Pharmaceuticals for Human Use (ICH)
  Australia adoption of M4E(R2)  119
Clinical Investigation of Medicinal Products in
  the Pediatric Population (E11)  53
  E11 general principles  60
  E11 recognition by Japan  113
  Ethnic Factors in the Acceptability of Foreign
  Clinical Data E5 (R1)  53
  GCP guidelines  60
  pediatric population categories  74
International Council for Harmonization
  of Technical Requirements for
  Pharmaceuticals for Human Use (ICH)
guidelines from  1–4
International Medical Device Regulators Forum
  (IMDRF)  3
  Australian participation in  122
International Neonatal Consortium (INC)  3
International Organization for Standardization
  (ISO)  3
International Program  7

J
Japan
  development incentives  115
  drug development  113
  foreign approval of drugs  114
  initiatives timeline (Japan)  115
  pediatric drug history  113
  Pediatric Drugs Working Group Stakeholder
  and Process  116
  regulatory agencies  113
  regulatory initiatives/incentives  115
  Unapproved Drugs/Indications Scheme  113
  unapproved drugs scheme  115
  Japan new drug application (JNDA)  114

K
Kazakhstan  156

L
labeling
  FDA requirements  29–31
  medical devices in Australia  123
  medical devices in New Zealand  125
  medicinal products in Australia  120
  pediatric medicines in New Zealand  124
  products in US  29
Latin America and Caribbean (LAC) region
  Argentina  64
  Brazil  65
  Chile  68
  Colombia  66
  considerations for sponsors  70
countries with orphan drug regulation  63
  Cuba  67
  Mexico  68
  National regulatory authorities  63
  regulatory initiatives  59
Latin America and Caribbean region
  countries in 59
  country demographics 61
leveraging clinical data 48
Life Saving Drugs Program (LSDP) 121

M
Malaysia 156
market access
  Argentina 65
  Brazil 66
  Canada 55
devices in New Zealand 126
India 151
New Zealand reimbursement requirements 124
  programs in LAC region 62
  requirements in Australia 121
RoW summary 162
Switzerland 111
UK assessment for 104
market exclusivity
  Japan 115
Marketing Authorization application (MAA)
  approval in Cuba 67
  Canada 55
deferral or waiver in UK 97
evaluation in Mexico 69
India 144, 151
Japanese standards for 116
LAC region 60
Latin America and Caribbean region 62
Paediatric Investigation Plan compliance 89
pediatric drug development (UK) 98
pediatric medicinal products 89–96
pediatric medicines in China 132–142
PIP compliance check for 89
  procedures in China 137
requirements in UK 97
RoW summary 161
Swissmedic requirements 108
timeline for Columbia 67
United Kingdom 101
medical device development
  Australian legal framework 121
classification 49
data extrapolation for pediatric use 48
general principles for 48
guidance on pediatric use 47
information on pediatric uses 47
New Zealand 125
United States 45
Medicines and Healthcare products Regulatory Agency (MHRA)
drug development tools 97
noncompliance 101
Paediatric Investigation Plan submission to 97
Medicines and Medical Devices Safety Authority (MEDSAFE) 124
memorandums of understanding ((MoU) India) 148
Mexico
  biological product clinical trials 69
  pharmaceutical market in 68
  pre-assessment evaluation process 69
  regulatory standards 68
Ministry of Health, Labour and Welfare (MHLW) 113
modeling and simulation use 28

N
national competent authorities (NCAs)
  compliance check 89
  PDCo member appointments 76
National Essential Drug List (NEDL) 140
National Health Commission (NHC) 129
National Institute for Health and Care Excellence (NICE) 104
National Institute of Drugs (INAME) 65
National Medical Products Administration (NMPA) 129
National Regulatory Authorities of regional reference (NRAr) 60
National Reimbursement Drug List (NRDL) 140
Neonatology Program 8
New Zealand
  guidelines recognized by 124
  legal and regulatory framework for medicines 124–127
  pediatric exclusivity orphan drug designation 124
  pediatric investigation plans in 124
Notice of Compliance (NOC) drugs 55
Notice of Compliance with Conditions (NOC/c) drugs 55
O

Observatorio Interinstitucional de Enfermedades Huerfanas (ENHU) 67
off-label use
  nonclinical study requirements 25
  pediatric device use 45
off-patent drug products 73
Organización Mexicana de Enfermedades Raras (OMER) 69
orphan diseases. See rare disease designation
orphan drug designation (ODD)
  Australian criteria for 121
  CDSCO discretion for 151
criteria for 33
orphan drug development programs 39
orphan medicinal products (OMPs)
  pediatric requirement in EU 77
  UK assessment criteria for 104
orphan regulations
  Paediatric Regulation re-evaluation 91
requirements 92

P

paediatric use marketing authorisation (PUMA) 73
Pan American Health Organization/World Health Organization (PAHO/WHO) 60
pan-Canadian Oncology Drug Review (pCODR) 56
Patented Medicine Prices Review Board (PMPRB) 55
patent protection
  China 132
  European Union 78, 87
patient engagement/advocacy
  advocates in Columbia 67
  Brazil 66
  Chile 68
  EU product development 93
  India 144
  Latin America and Caribbean regions 64
  Mexican organizations 69
  MHRA pilot program for 98
  Unapproved Drugs/Indications Scheme 113
Patient Group Consultative Forum (PGCF) 98
Patients’ and Consumers’ Working Party (PCWP) 93
Paediatric Use Marketing Authorisation (PUMA) 3, 90
Pediatric Advisory Committee 11
Pediatric Cluster meetings/calls 2–4
  Australia participation in 121
  Canadian participation 53
Pediatric Committee (PDCO)
  compliance checks 89
  composition and functions 75
Pediatric Device Consortia (PDC) Grant Program 51
Pediatric Drug Action Plan (PDAP) 54
Pediatric Drugs Working Group (PMDA) 114
pediatric exclusivity 7
  Australia 120
  New Zealand 124
  United States 14
Pediatric Exclusivity Board 7
pediatric investigation plan
  deferrals (UK) 97
  EU requirements 77
  exemptions from (EU) 77
  foreign medicines acceptance 108
  PDSCO assessment of 76
  submission and obligation for Swissmedic 108
  waivers (Swissmedic) 109
  waivers (UK) 97
Paediatric Investigation Plan (EU)
  compliance check 89
  content of 83, 81–96
  deferrals 89, 89–96
  incentives 90
  interaction with EMA bodies 92–96
  marketing authorization 89–96
  marketing for pediatric population 90
  modification of 87
  Paediatric Regulation requirement for 73
  PDSCO opinion on 86
  postauthorisation measures in 90
  procedures for 79
  requirements 77
  rewards and incentives 87
  submission timing 78
  waivers for 87
Paediatric Investigation Plan (UK)
- adopted and agreed 100
- modifications of 100
- regulatory requirements in UK 97
- requirements for 98, 99
- submissions after 1 January 2021 100
- submission timeline for 98
- transitional provisions 98
- waivers for 101

pediatric population
- age categorization in 55
- Australia definitions 120
- competition for trials 59
- EU definition 74, 94
- FDA definition 5, 45
- infants/toddlers 5
- neonates 5

Paediatric Regulation (PR)
- actions of 73
- European database introduction 91
- possible revisions 91
- requirements of 77
- Switzerland 107
- UK alignment with 97

Pediatric Research and Equity Act (PREA) 8, 9

Pediatric Review Committee (PeRC) 11

Pediatric Rule (US) 5

Pediatric Study Plan (PSP)
- contents 17
- interactions with FDA 12
- organ system differences in 25, 26
- Planned 19
- procedures for iPSP 15–31
- study design 12
- submission of 11
- timeline for development plan 18
- written request for 12

Pediatric Ventricular Assist Device approval 50

Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy 114

Pharmaceutical and Medical Device Agency (PMDA) 113, 114

Pharmaceutical and Medical Safety Bureau (PMSB) Notification 115

Pharmaceutical Benefit Scheme (PBS) 121

Pharmaceutical Management Agency of New Zealand (PHARMAC) 124

Philippines 156

placebo-controlled trials 64

postauthorisation measures (PAMs) 90

post-marketing surveillance review 115

premarket assessment and pathways for devices 47, 49

recent device submissions 50

priority review
- Argentina 65
- Brazil 66
- China 132–142, 137
- Cuba 67
- Latin America and Caribbean region 62

voucher program 11, 35–43

product development
- clinical studies 27
- clinical studies (US) 27–31
- criteria for 55
- drug development (EU) 75
- drugs 144–153
- drugs (India) 143
- drugs (Japan) 113
- European Union (EU) 73
- expedited development for 33
- expedited orphan drugs 39
- initiatives for devices 51
- nonclinical studies (US) 24
- patient engagement in 93, 108
- pediatric formulations 23
- pediatric labeling (US) 29
- premarket device submission 50

Regulations 114

requirements in Mexico 69

standards in Columbia 66

tools for device development 46

United States 23

Public Paediatric study Assessment Reports (PdPAR) 104

R

rare disease designation 67
- Argentina 65
- Brazil 66
- Columbia 67
- definition and identification of 33
- United States 33

Rare Pediatric Disease Designation (RPDD) program 35

regenerative medicine products 113
regulatory agencies/authorities
Argentina 64
Brazil 65
Chilean Regulatory Authority 68
China 129
Cuba 67
Health Canada 56
Latin America and Caribbean region 60, 63
Medicines and Healthcare products Regulatory Agency 97
Medicines and Medical Devices Safety Authority (MEDSAFE) 124
Mexican Regulatory Authority 69
Ministry of Health, Labour and Welfare (MHLW) 113
national competent authorities (NCAs) 76
National Regulatory Authorities of regional reference (NRAr) 60
New Zealand 125, 126
Pan American Health Organization/World Health Organization (PAHO/WHO) 60
Pharmaceutical and Medical Device Agency (PMDA) 113
Swissmedic 107
Therapeutic Goods Administration 119
regulatory framework
Australia/New Zealand 119
China 129, 131
device development in Australia 122
drug regulations (Canada) 53
Drugs and Cosmetics Rules (India) 144
Human Medicines Regulations 97
Human Medicines Regulations (UK) 97
LAC countries with orphan regulations 63
medical devices in New Zealand 125
Medicines Act/Medicines Regulations (New Zealand) 124
New Drugs and Clinical Trials Rules (India) 151
New Zealand 119
Paediatric Regulation (PR) 73
pediatric device development 46
Pharmaceutical and Medical Devices (PMD) Act 113
Switzerland 107
Therapeutic Product Act and revision 107
United Kingdom 97
United States 5–31
regulatory initiatives/incentives
Argentina 65
Australia 120
Brazil 65, 66
China 130–142
data protection system 115
EU 75
global 1
Health Canada 53
incentives 111
India 151
Indian tax law and 152
Japan 115, 116
Latin America and Caribbean region 59
market exclusivity 115
patent protection 87
Pediatric Drug Action Plan (PDAP) (Canada) 54
pediatric drug price reimbursement 115
pediatric products (EU) 87
Supplementary Protection Certificate (SPC) 108
under Paediatric Regulation 90
United Kingdom 97
reimbursement/pricing
Canada 56
China 139
Japan 115
New Zealand 124
orphan drugs in India 151
RoW summary 162
Rest of the World (RoW)
clinical trial and marketing authorization requirements 161
country demographics 155–163
development tools availability summary 160
drug and device requirements 155
market access, reimbursement/pricing 162
regulatory initiatives/incentives summary 159
Russia 157
S
Safety Program 7
safety updates (UK) 99
Saudi Arabia 157
Scientific Activities Program 7
Scientific Advice Working Party (SAWP) 92
Scottish Medicine Consortium (SMC) 104
“seed-stage” research 114
self-care environment. See also self-management
Singapore 157
Sistema Único da Saúde (SUS) 66
Social Security Health System (SGSSS) 66
South Korea 158
Summary of Product Characteristics (SmPC) 87
supplementary protection certificate (SPC) 87
Switzerland 111
Supplementary Protection Certificate (SPC) 87
Switzerland
deferral of measures 109
fulfillment conditions after authorization 110
laws and regulations 107
market access 111
new vs existing PIP 109
patient engagement 108
pediatric drug development background 107
pediatric incentives 111
PIP approved by foreign authority 110
PIP content template 110
PIP process/assessment 109
product information 109, 110
regulatory requirements 107
waivers for PIP 109
synthetic drug evaluation process 65
System of Hospitals for Innovation in
Pediatrics–Medical Devices (SHIP-MD) 51

T
Taiwan 158
Technology Appraisal (TA) program 104
Thailand 158
Therapeutic Goods Administration
Australian device clinical guidelines 123
Therapeutic Goods Administration (TGA)
ICH guideline adoption 119
Turkey 159
21st Century Cures Act 11

U
ultra-orphan drugs 104
Unapproved Drugs/Indications Scheme (Japan) 113

V
Vietnam 160
Index

W
World Health Organization (WHO)
  monitoring in RoW  162
  role in child health  1
written request (WR)
  content of  12